Bruno Bomfim da Silva Bockorny, MD
Internal Medicine · Boston, MANPI 1376850123
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,032 of the $5,957 with a category attached, or 67.7%. Blueprint Medicines Corporation accounts for 67.7% of it on its own, with 1 other manufacturer making up the rest. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2 payments — averaging $2978.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$4K
- Springworks Therapeutics, Inc.$2K
Across 159 payments — averaging $7747.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$640K
- Seagen Inc.$347K
- Novartis$122K
- Merck$62K
- Incyte Corporation$58K
- Gilead$2K
What the payments were for
- Consulting fees$1,92532%
- Speaking & faculty fees$4,03268%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 1 | $4,032 |
| Springworks Therapeutics, Inc. | 1 | $1,925 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OGSIVEO$1,925
How this compares
$5,957 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TazverikTazemetostat Hydrobromide | 18 | $345,172 |
| NeulastaPegfilgrastim | 13 | $158,990 |
| CreonLipase/Protease/Amylase | 28 | $69,869 |
| EliquisApixaban | 38 | $30,565 |
| Sucralfate | 13 | $944 |
| Olanzapine | 33 | $647 |
| Oxycodone Hcl | 35 | $289 |
| Dexamethasone | 17 | $249 |
| Omeprazole | 22 | $223 |
| Prochlorperazine Maleate | 17 | $165 |
| LoperamideLoperamide Hcl | 11 | $129 |
| Methylphenidate Hcl | 16 | $110 |
| Ondansetron Hcl | 12 | $94 |
| Amlodipine Besylate | 15 | $86 |
| Potassium Chloride | 12 | $74 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Boston
- David SchenkeinBoston$5M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
- Nancy GaglianoBoston$358K
- Fatima StanfordBoston$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.